Molecular targets of diabetic vascular complications and potential new drugs

Roberto Da Ros, Roberta Assaloni, Antonio Ceriello

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

In diabetes, oxidative stress plays a key role in the pathogenesis of vascular complications, and an early step of such damage is considered to be the development of an endothelial dysfunction. Hyperglycemia directly promotes an endothelial dysfunction inducing process of overproduction of superoxide and consequently peroxynitrite, that damages DNA and activates the nuclear enzyme poly(ADP-ribose) polymerase. This process, depleting NAD+, slowing glycolsis, ATP formation and electron transport, results in acute endothelial dysfunction in diabetic blood vessels and contributes to the development of diabetic complications. These new findings may explain why classical antioxidants, like vitamin E, that work scavenging already formed toxic oxidation products, have failed to show beneficial effects on diabetic complications, and suggest new and attractive "causal" antioxidant therapy. New, low molecular mass compounds that act as SOD or catalase mimetics or L-propionylcarnitine and lipoic acid, that work as intracellular superoxide scavengers, improving mitochondrial function and reducing DNA damage, may be good candidates for such strategy, and preliminary studies support this hypothesis. This "causal" therapy would also be associated with other promising tools such as LY 333531, PJ34 and FP15, which block protein kinase β isoform, poly(ADP-ribose) polymerase and peroxynitrite, respectively. It is now evident that, statins, ACE inhibitors, AT-1 blockers, calcium channel blockers and thiazolidinediones have a strong intracellular antioxidant activity, and it has been suggested that many of their beneficial ancillary effects are due to this property. This preventive activity against oxidative stress generation can justify a large utilization and association of this compounds for preventing complications in diabetic patients where antioxidant defences have been shown to be defective.

Original languageEnglish
Pages (from-to)503-509
Number of pages7
JournalCurrent Drug Targets
Volume6
Issue number4
DOIs
Publication statusPublished - Jun 2005

Fingerprint

Diabetic Angiopathies
Diabetes Complications
Antioxidants
propionylcarnitine
Peroxynitrous Acid
Oxidative stress
Poly(ADP-ribose) Polymerases
Superoxides
Pharmaceutical Preparations
DNA Damage
ruboxistaurin
Blood Vessels
Oxidative Stress
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Thioctic Acid
Thiazolidinediones
Poisons
DNA
Scavenging
Blood vessels

Keywords

  • ACE inhibitors
  • ATI receptor inhibitors
  • Calcium channel blockers
  • Diabetic complications
  • Oxidative stress
  • Statins
  • Thiazolidinediones

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science

Cite this

Molecular targets of diabetic vascular complications and potential new drugs. / Da Ros, Roberto; Assaloni, Roberta; Ceriello, Antonio.

In: Current Drug Targets, Vol. 6, No. 4, 06.2005, p. 503-509.

Research output: Contribution to journalArticle

Da Ros, Roberto ; Assaloni, Roberta ; Ceriello, Antonio. / Molecular targets of diabetic vascular complications and potential new drugs. In: Current Drug Targets. 2005 ; Vol. 6, No. 4. pp. 503-509.
@article{f86b453febf84190806e895c9957214f,
title = "Molecular targets of diabetic vascular complications and potential new drugs",
abstract = "In diabetes, oxidative stress plays a key role in the pathogenesis of vascular complications, and an early step of such damage is considered to be the development of an endothelial dysfunction. Hyperglycemia directly promotes an endothelial dysfunction inducing process of overproduction of superoxide and consequently peroxynitrite, that damages DNA and activates the nuclear enzyme poly(ADP-ribose) polymerase. This process, depleting NAD+, slowing glycolsis, ATP formation and electron transport, results in acute endothelial dysfunction in diabetic blood vessels and contributes to the development of diabetic complications. These new findings may explain why classical antioxidants, like vitamin E, that work scavenging already formed toxic oxidation products, have failed to show beneficial effects on diabetic complications, and suggest new and attractive {"}causal{"} antioxidant therapy. New, low molecular mass compounds that act as SOD or catalase mimetics or L-propionylcarnitine and lipoic acid, that work as intracellular superoxide scavengers, improving mitochondrial function and reducing DNA damage, may be good candidates for such strategy, and preliminary studies support this hypothesis. This {"}causal{"} therapy would also be associated with other promising tools such as LY 333531, PJ34 and FP15, which block protein kinase β isoform, poly(ADP-ribose) polymerase and peroxynitrite, respectively. It is now evident that, statins, ACE inhibitors, AT-1 blockers, calcium channel blockers and thiazolidinediones have a strong intracellular antioxidant activity, and it has been suggested that many of their beneficial ancillary effects are due to this property. This preventive activity against oxidative stress generation can justify a large utilization and association of this compounds for preventing complications in diabetic patients where antioxidant defences have been shown to be defective.",
keywords = "ACE inhibitors, ATI receptor inhibitors, Calcium channel blockers, Diabetic complications, Oxidative stress, Statins, Thiazolidinediones",
author = "{Da Ros}, Roberto and Roberta Assaloni and Antonio Ceriello",
year = "2005",
month = "6",
doi = "10.2174/1389450054021855",
language = "English",
volume = "6",
pages = "503--509",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Molecular targets of diabetic vascular complications and potential new drugs

AU - Da Ros, Roberto

AU - Assaloni, Roberta

AU - Ceriello, Antonio

PY - 2005/6

Y1 - 2005/6

N2 - In diabetes, oxidative stress plays a key role in the pathogenesis of vascular complications, and an early step of such damage is considered to be the development of an endothelial dysfunction. Hyperglycemia directly promotes an endothelial dysfunction inducing process of overproduction of superoxide and consequently peroxynitrite, that damages DNA and activates the nuclear enzyme poly(ADP-ribose) polymerase. This process, depleting NAD+, slowing glycolsis, ATP formation and electron transport, results in acute endothelial dysfunction in diabetic blood vessels and contributes to the development of diabetic complications. These new findings may explain why classical antioxidants, like vitamin E, that work scavenging already formed toxic oxidation products, have failed to show beneficial effects on diabetic complications, and suggest new and attractive "causal" antioxidant therapy. New, low molecular mass compounds that act as SOD or catalase mimetics or L-propionylcarnitine and lipoic acid, that work as intracellular superoxide scavengers, improving mitochondrial function and reducing DNA damage, may be good candidates for such strategy, and preliminary studies support this hypothesis. This "causal" therapy would also be associated with other promising tools such as LY 333531, PJ34 and FP15, which block protein kinase β isoform, poly(ADP-ribose) polymerase and peroxynitrite, respectively. It is now evident that, statins, ACE inhibitors, AT-1 blockers, calcium channel blockers and thiazolidinediones have a strong intracellular antioxidant activity, and it has been suggested that many of their beneficial ancillary effects are due to this property. This preventive activity against oxidative stress generation can justify a large utilization and association of this compounds for preventing complications in diabetic patients where antioxidant defences have been shown to be defective.

AB - In diabetes, oxidative stress plays a key role in the pathogenesis of vascular complications, and an early step of such damage is considered to be the development of an endothelial dysfunction. Hyperglycemia directly promotes an endothelial dysfunction inducing process of overproduction of superoxide and consequently peroxynitrite, that damages DNA and activates the nuclear enzyme poly(ADP-ribose) polymerase. This process, depleting NAD+, slowing glycolsis, ATP formation and electron transport, results in acute endothelial dysfunction in diabetic blood vessels and contributes to the development of diabetic complications. These new findings may explain why classical antioxidants, like vitamin E, that work scavenging already formed toxic oxidation products, have failed to show beneficial effects on diabetic complications, and suggest new and attractive "causal" antioxidant therapy. New, low molecular mass compounds that act as SOD or catalase mimetics or L-propionylcarnitine and lipoic acid, that work as intracellular superoxide scavengers, improving mitochondrial function and reducing DNA damage, may be good candidates for such strategy, and preliminary studies support this hypothesis. This "causal" therapy would also be associated with other promising tools such as LY 333531, PJ34 and FP15, which block protein kinase β isoform, poly(ADP-ribose) polymerase and peroxynitrite, respectively. It is now evident that, statins, ACE inhibitors, AT-1 blockers, calcium channel blockers and thiazolidinediones have a strong intracellular antioxidant activity, and it has been suggested that many of their beneficial ancillary effects are due to this property. This preventive activity against oxidative stress generation can justify a large utilization and association of this compounds for preventing complications in diabetic patients where antioxidant defences have been shown to be defective.

KW - ACE inhibitors

KW - ATI receptor inhibitors

KW - Calcium channel blockers

KW - Diabetic complications

KW - Oxidative stress

KW - Statins

KW - Thiazolidinediones

UR - http://www.scopus.com/inward/record.url?scp=21444439237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21444439237&partnerID=8YFLogxK

U2 - 10.2174/1389450054021855

DO - 10.2174/1389450054021855

M3 - Article

C2 - 16026269

AN - SCOPUS:21444439237

VL - 6

SP - 503

EP - 509

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 4

ER -